Chronic myeloid leukemia (CML) is caused by the BCR-ABL hybrid gene. The molecular mechanisms leading from chronic phase (CP) to blast crisis (BC) are not understood. However, both the presence and the levels of BCR-ABL seem to be important for CML progression. BCR-ABL is under the transcriptional control of BCR promoter. Here we focused on the gene expression control of BCR and BCR-ABL upon myeloid differentiation in healthy donors (HDs), CP and BC patients. As previously reported, BCR-ABL is downregulated during myeloid maturation in CP patients. A similar pattern was detected for BCR (but not for ABL) in CP-CML and in HD, thus suggesting that the two genes may be under a similar transcriptional control. In BC this mechanism is similarly impaired for both BCR-ABL and BCR. These data indicate the presence of an 'in trans' deregulated transcription of both BCR and BCR-ABL promoters, associated with CML progression.
Introduction
Chronic myeloid leukemia (CML) is characterized by the t(9;22) chromosomal translocation resulting in the formation of the BCR-ABL fusion gene. 1, 2 CML is characterized by an initial chronic phase (CP), in which the differentiation of leukemic cells in the bone marrow is preserved. Years after the onset of CP, patients eventually progress to an intermediate phase (accelerated phase) and then to the acute, final phase of the disease (blast crisis, BC). In the latest stage, the differentiation potential of the leukemic cells is lost and blast cells accumulate in the bone marrow and peripheral blood.
Recently, Jamieson et al. 3 showed that in CP, BCR-ABL mRNA level decreased during myeloid differentiation. Conversely, in samples from patients in BC, no downregulation of BCR-ABL was detectable during myeloid maturation. This correlated with an expansion of myeloid progenitors and with a marked increase of activated b-catenin. BCR-ABL is known to control b-catenin protein stabilization through tyrosine phosphorylation. Phosphotyrosine b-catenin is resistant to GSK3b-dependent degradation and binds to the TCF4 transcription factor (TF), thus representing a transcriptionally active pool. 4 The block in myeloid differentiation of bone marrow progenitors and the acquired inability to differentiate in mature cells are the main characteristics of the BC-CML cells. Previous works showed that the BCR-ABL expression level is critical for this differentiation block. 5 CEBPa represents the principal inducer of granulocytic differentiation; in BC-CML primary cells, CEBPa protein is almost undetectable, although its mRNA is expressed at high levels. 6 Perrotti et al. 6 showed that BCR-ABL upregulates the expression of hnRNPE2, an RNA-binding protein that, by its interaction with CEBPa mRNA, inhibits CEBPa translation and causes its suppression at the protein level: thus hnRNPE2 and CEBPa protein expression levels inversely correlate. In CP-CML myeloid precursors, where BCR-ABL expression is low, hnRNPE2 is downmodulated and CEBPa protein is expressed. CEBPa is thus able to induce the differentiation of the myeloid precursors into mature cells. In BC-CML myeloid precursors the mechanisms causing BCR-ABL downmodulation are lost and BCR-ABL is detectable at high levels. 3 This leads to hnRNPE2 upregulation, inhibition of CEBPa expression, upregulation of activated b-catenin and, eventually, to the loss of the differentiation potential of the BC myeloid precursors. This hypothesis is further supported by the ability of BCR-ABL to block myeloid differentiation. 5, 6 Overall, these data suggest that the 'oncogene dosage' is a determinant factor for the differentiation block in BC-CML and that the progression to BC could be linked to an abnormal control of BCR-ABL expression during myeloid differentiation with ensuing maturation block. Unfortunately, the mechanisms leading to the deregulated expression of BCR-ABL in BC are not known. The loss of BCR-ABL downregulation upon myeloid differentiation could be due to an 'in trans' dysregulation of its promoter, affecting the expression of BCR-ABL but also BCR. Alternatively, a genetic lesion at BCR-ABL locus, acting through an 'in cis' mechanism, could affect only BCR-ABL expression, leaving BCR under the normal transcriptional control. This scenario is further complicated by the evidence that miRNA203 is able to downmodulate ABL and BCR-ABL expression through a direct interaction with ABL and BCR-ABL 3 0 UTR, causing a decrease in ABL and BCR-ABL mRNA half-life. 7 Moreover, the mechanisms involved in the physiological regulation of BCR upon myeloid differentiation are yet unknown. 8, 9 To investigate these alternative hypotheses and to analyze BCR expression pattern upon myeloid differentiation, we characterized BCR levels in sorted myeloid precursors in healthy donors (HDs) and in CML patients in CP and BC. CML samples were also analyzed for BCR-ABL expression in each subpopulation.
Materials and methods
Normal bone marrow or peripheral blood samples were obtained after written informed consent in agreement with the Declaration of Helsinki Principles from 7 HDs, 10 CP-CML (not in cytogenetic remission) and 7 BC-CML patients.
Hematopoietic stem cells (HSCs), common myeloid progenitors (CMPs) and granulocyte-macrophage progenitors (GMPs) were isolated from mononuclear cells by fluorescence-activated cell sorting and magnetic cell sorting techniques. Samples were subjected to a purification/enrichment using magnetic cell sorting systems (MACS lineage cell depletion kit; Miltenyi Biotech, Bergisch Gladbach, Germany) with the following cocktail of antibodies: CD2, CD3, CD10, CD11b, CD14, CD15, CD16, CD19, CD56, CD123 and glycophorin A. Subsequently, the myeloid subpopulation was sorted by fluorescence-activated cell sorting (FACSAria; Becton Dickinson, Franklin Lakes, NJ, USA) in the following subpopulations: HSCs (LinÀ, CD34 þ /CD38À/Thy þ /À); CMPs (LinÀ, CD34 þ / CD38 þ /IL-3Ralo/CD45RAÀ) and GMPs (LinÀ, CD34 þ / CD38 þ /IL-3Ralo/CD45RA þ ) as described by Manz et al.
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RNA was isolated by RNeasy Micro Kit (Qiagen, Hilden, Germany) and retrotranscribed (MultiScribe Reverse Transcriptase; Applied Biosystems, Foster City, CA, USA). Quantitative PCR analysis for BCR, ABL, BCR-ABL and GUS was performed using a specific sets of primers reported in Table 1. 11,12 BCR, ABL and BCR-ABL levels were normalized against GUS and analyzed with the statistical software package Prism 4 (GraphPad, La Jolla, CA, USA). K562 cells were cultured with RPMI and fetal bovine serum 10%.
RNA stability assay
Actinomycin D (5 mM) was added to cultures for up to 24 h. Total RNA was prepared at the time points indicated in Figure 2 . BCR and BCR-ABL expression levels were analyzed by quantitative PCR.
The human BCR promoter was cloned by PCR from human genomic DNA extracted from an HD with the following strategy: a reverse primer carrying an artificial HindIII site was designed to bind to the 3 0 region of the promoter, in correspondence to the first coding ATG sequence, which defines the coding protein region. This primer was used to amplify all the constructs. The sequence of the forward primers, carrying an artificial NheI restriction site at their 5 0 , changed accordingly with the target region (see Table 2 for sequence details). The two restriction sites were added to allow for the directional cloning into the pGL3 basic luciferase vector. We produced different constructs of BCR promoter with specific length, to identify the most transcriptionally active regions. We obtained the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) was used to measure the Firefly and Renilla Luciferase activities according to the manufacturer's instruction. The Firefly luminescence was normalized with Renilla Luciferase signal.
The experiments were performed in the K562 cell line, in triplicate. K562 cells were transfected by electroporation, using the following conditions: 270 V and 0.975 mF. Luciferase and Renilla signals were detected by MicroBeta (PerkinElmer, Waltham, MA, USA) system.
Statistical analysis
All the statistical analyses (unpaired two-tailed t-test, mRNA half-life) were performed with the GraphPad Prism (GraphPad) statistical package.
Results
In HDs, BCR levels are significantly downregulated upon myeloid maturation (Figure 1a The analysis of BCR expression was extended to CP-CML patients, where BCR is similarly downregulated upon differentiation to the more mature phenotype (Figure 1c , HSCs 0.301±0.045; CMPs 0.102±0.011; GMPs 0.043±0.015; HSCs vs CMPs, P ¼ 0.0039; HSCs vs GMPs, P ¼ 0.0003). The higher levels of BCR in HD than in CP-CML samples (2.8-fold in HSCs, 1.5-fold in CMPs and 3.1-fold in GMPs) could be due to the presence of a single copy of the BCR gene in CML cells.
The evidence of a downmodulation of BCR upon myeloid differentiation suggests that the mechanisms controlling the expression of BCR in the normal hematopoiesis are conserved in CP-CML. In line with previously published results, 3 the analysis of BCR-ABL expression in our CP-CML population showed the downregulation of BCR-ABL mRNA expression upon myeloid differentiation (Figure 1d , HSCs 3.155 ± 0.338; CMPs 0.806 ± 0.084; GMPs 0.485 ± 0.108; HSCs vs CMPs, P ¼ 0.0003; HSCs vs GMPs, Po0.0001).
To assess if ABL is similarly regulated during differentiation, we analyzed ABL expression in five HDs. We failed to detect ABL downmodulation upon differentiation in these samples (Figure 1b , HSCs 0.22±0.17; CMPs 0.16±0.13 and GMPs 0.152 ± 0.135; HSCs vs CMPs, P ¼ 0.42 and HSCs vs GMPs, P ¼ 0.55). These data suggest that the mechanisms controlling BCR and ABL expression during myeloid differentiation are The analysis of BCR expression in the same set of BC patients showed a similar pattern, with a loss of BCR downmodulation in the GMPs population (Figure 1e , HSCs 0.226±0.048; CMPs 0.081 ± 0.019; GMPs 0.296 ± 0.1205). Similarly to BCR-ABL, the expression of BCR was significantly higher in BC than in CP in the GMPs subpopulation (0.296 ± 0.1205 vs 0.043 ± 0.015, respectively; P ¼ 0.0226). These findings indicate that the loss of BCR-ABL downmodulation in BC is caused by an 'in trans' mechanism, affecting also the expression of BCR.
To investigate if these findings could be due to differences in mRNA stability, similar to those caused by miR203, 7 we determined BCR and BCR-ABL mRNA half-life (Figure 2) . No significant differences in BCR-ABL mRNA stability could be detected (CP-CML BCR half-life is 3.2 h, whereas BCR-ABL is 2.0; P ¼ 0.0523; BC-CML BCR half-life is 1.8 h, BCR-ABL is 2.2; P ¼ 0.774; in K562 BCR and BCR-ABL half-lives are 3.0 and 2.3 h; P ¼ 0.956).
To identify the regions of BCR promoter involved in the activation of BCR transcription, we cloned different BCR promoter constructs in a luciferase reporter vector and we performed a gene report assay to study the transcriptional activity of BCR promoter in the K562 cell line (Figure 3) . A minimal promoter was previously identified, 8 corresponding to a 1-kb region immediately upstream of exon 1 coding sequence. 8, 9 We extended our study to 452 bp upstream from this minimal promoter, because several putative protein binding sites have been identified in this region by DNase protection studies, 9 to a total of 1443 bp, corresponding to the longest construct used here (pGL3/BCR). The importance or the transcriptional influence of these regions is yet unknown. The main transcription start site was identified at À471 bp from the ATG sequence, 8 and other minor transcription start sites have been identified in the region between the main transcription start site and the coding sequence (Figure 3) . On the basis of this information, we cloned the D1041 and D1271 constructs of BCR promoter, corresponding to 418 and 170 bp upstream from the coding sequence, containing three minor transcription start sites (indicated in Figure 3 ) but not the main start site, to analyze the contribution of these regions to the transcriptional activity. To investigate the region upstream from the main transcriptional start site, we generated three additional constructs, D541, D241 and the pGL3/BCR, spanning 896, 1203 and 1443 bp upstream from the ATG sequence. In these three constructs the main transcription start site and a putative SP1 binding site, 8 located 69 bp upstream from the main transcription start site, are present.
D1041 and D1271 showed a very low level of luciferase activity, comparable to that of the empty vector (Figure 3) , as expected. This is in line with previous reports showing that only minor transcriptional start sites could be found in this region, 8, 9 and suggesting that the DNase protected regions identified in this part of the BCR promoter do not have a major role in the activation of BCR transcription. In contrast, when we analyzed the D541 construct, the luciferase activity was significantly increased over the empty vector (19-fold increase, P ¼ 0.0011). This finding was not unexpected, because in D541 the presence of the main transcription site and of a putative SP1 binding site has been previously reported. 8 D241 construct showed a level of luciferase activity (13-fold increase, P ¼ 0.0061) similar to D541. The luciferase activity of the longest BCR promoter (pGL3/BCR) showed a 49-fold increase in the luciferase activity in comparison to the empty vector (P ¼ 0.0006), significantly higher than D541 and D241 (P ¼ 0.0048 and P ¼ 0.0023). These data indicate that the region between À1443 and À1202 bp from the ATG site could be critical for the transcriptional activity of the BCR promoter.
Discussion
We found that BCR, but not ABL, is physiologically downregulated upon myeloid maturation from HSCs to CMPs and GMPs, and that this mechanism is conserved in CP, for both BCR and BCR-ABL. In BC this regulation is lost and this is Figure 3 In a, the BCR promoter representation is reported: the mutant lacking the upstream promoter sequence was constructed in a promoterdevoid luciferase vector, pGL3-basic; the forward primers used for BCR promoter constructs cloning are indicated by the thin arrows, the reverse primer is the same for all BCR promoter forms (sequences in Table 2 apparently caused by the presence of an 'in trans' mechanism acting on both BCR and BCR-ABL, which selectively impairs the downmodulation of the two genes in the more mature myeloid subpopulations (GMPs). Recently, a novel in-frame splice deletion of GSK3B gene has been identified in some CP and BC patients. Active GSK3B promotes b-catenin degradation and inhibits protein synthesis; the misspliced GSK3B could increase b-catenin expression and this could cause the transcription of some TFs. 13 One or more of these TF could be involved in BCR and BCR-ABL regulation.
The results of the luciferase assay indicate that the region comprised between 420 and 900 bp from the coding ATG site is required to achieve a basal transcription level. Previous studies 9 suggest that a putative SP1 binding site could have a role in the basal promoter activity. In fact, an almost complete absence of transcriptional activity was measured in D1041 and D1271 constructs, lacking both the main transcription start site and the putative SP1 binding region. We hypothesize that SP1 could be responsible for the basal promoter activity, present in the D541 and in longer constructs. The consensus binding site for SP1 was previously identified in the BCR promoter. 9 The presence of 10 additional putative protein binding sites (PBSs), along the BCR promoter is also known from previous works 8, 9 ( Figure 3 ). Six of these putative PBSs are localized in the region between À1443 to À1202 bp, which appears to be critical from in silico studies. In fact, only in presence of a 221 bp region upstream from D241, a strong luciferase signal could be detected, suggesting that the promoter region between À1443 and À1202 bp from the coding ATG is indeed critical to achieve the highest level of expression. In silico analysis showed that different TFs could be involved in the regulation of BCR promoter activity in the À1443 to À1202 region: Sry could bind close to PBS1, whereas c-myc and its co-factor Max could localize in PBS2; also C/EBP box motif (CCAAT) is predicted to bind in the same region. Putative E47 and AML1 binding sites are present in PBS3; finally USF could bind in PBS4. The interactions between the TF and BCR-ABL could, however, be more complicated than expected. For example, c-myc, has been identified as being regulated by b-catenin and this evidence supports a possible role of this TF in the progression of CML, when the b-catenin is overexpressed in BC.
14 However, BCR-ABL protein also induces the expression of c-myc 15 by the mitogen-activated protein kinase-dependent regulation of HNRPK translation regulatory activity. Therefore, an alteration of the transcriptional activity present in the PBS2 region could theoretically be involved in disease progression, in accordance with the results of BCR and BCR-ABL expression in normal individuals and in CP and BC patients. In fact, both genes show a similar pattern of expression in all phases of CML disease. This suggests that an 'in trans' deregulation of the transcriptional activity of BCR promoter likely contributes to the progression of CML.
The role of these TFs in the transcriptional activity of BCR promoter is now being experimentally investigated, including the presence of methylated CpGs islands, that could change the binding of TFs. In addition, the investigation of the causes of BCR deregulation in BC is presently being addressed by high-throughput sequencing (including ChIP-Seq and mRNA-Seq), protein/DNA arrays techniques and additional in silico analysis of putative binding sites present in the BCR promoter.
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